title: The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.
abstract: OBJECTIVE
  To examine treatment-specific changes in health-related quality of life (QOL) among patients with schizophrenia and to assess the association between clinical and QOL improvement.
  
  
  METHODS
  This post hoc analysis used the findings of a 28-week, randomized, multicenter trial of patients with schizophrenia (DSM-IV) treated with olanzapine (10-20 mg/day) or ziprasidone (80-160 mg/day). Data were collected from August 2001 to December 2002. Efficacy was measured using the Positive and Negative Syndrome Scale (PANSS). Quality of life was assessed with the generic health self-administered Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36) and the disease-specific expert-administered Heinrichs-Carpenter Quality of Life Scale (QLS). Mixed-effects-repeated-measures and last-observation-carried-forward approaches were used to assess the effects of treatment on QOL and the association of clinical outcomes to QOL outcomes.
  
  
  RESULTS
  Olanzapine- and ziprasidone-treated patients demonstrated similar improvement from baseline to endpoint on the SF-36 and QLS. All correlations between changes in PANSS scores and the SF-36 were significant (p < .001), ranging from -0.159 to -0.400. All correlations between changes in PANSS scores and the QLS were significant (p < .0001), ranging from -0.286 to -0.603. The correlations between the 2 QOL measures were generally significant but small to moderate in magnitude.
  
  
  CONCLUSIONS
  The results of this study indicate that, in patients with schizophrenia, olanzapine and ziprasidone treatment are associated with significant QOL and clinical improvements. Further, the significant correlation between change scores on the PANSS and QOL measures suggests that treatment-related clinical improvements are associated with improved health-related and disease-specific QOL.
  
  
  BACKGROUND
  ClinicalStudyResults.org identifier 2347.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN 46285, USA. phillipsga@lilly.com
authors.forename: Glenn A
authors.initials: GA
authors.lastname: Phillips
authors.forename: David L
authors.initials: DL
authors.lastname: Van Brunt
authors.forename: Suraja M
authors.initials: SM
authors.lastname: Roychowdhury
authors.forename: Wen
authors.initials: W
authors.lastname: Xu
authors.forename: Dieter
authors.initials: D
authors.lastname: Naber
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D004311:Double-Blind Method; D006304:Health Status; D006801:Humans; D008137:Longitudinal Studies; D000077152:Olanzapine; D010879:Piperazines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011788:Quality of Life / Q000523:psychology*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; C092292:ziprasidone; D000077152:Olanzapine